Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.5 (1y: -77%)
Market Cap 23.8 M P/E(ttm)
Enterprise Value 14.09 M P/B
ASTM- NAS (USA)
Aastrom Biosciences, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$0.50
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry		 vs
history
Cash to Debt 340.95
ASTM's Cash to Debt is ranked higher than
79% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ASTM: 340.95 )
ASTM' s 10-Year Cash to Debt Range
Min: 18.28   Max: No Debt
Current: 340.95
Equity to Asset -2.115
ASTM's Equity to Asset is ranked lower than
63% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ASTM: -2.115 )
ASTM' s 10-Year Equity to Asset Range
Min: -2.12   Max: 0.97
Current: -2.12
-2.12
0.97
Interest Coverage No Debt
ASTM's Interest Coverage is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ASTM: No Debt )
ASTM' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -38.15
M-Score: -4.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -160761.90
ASTM's Operating margin (%) is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ASTM: -160761.90 )
ASTM' s 10-Year Operating margin (%) Range
Min: -161333   Max: -731.8
Current: -160761.9
-161333
-731.8
Net-margin (%) -140352
ASTM's Net-margin (%) is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ASTM: -140352 )
ASTM' s 10-Year Net-margin (%) Range
Min: -140352   Max: -659.2
Current: -140352
-140352
-659.2
ROA (%) -194.2
ASTM's ROA (%) is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ASTM: -194.2 )
ASTM' s 10-Year ROA (%) Range
Min: -254.1   Max: -34.8
Current: -194.2
-254.1
-34.8
Revenue Growth (%) -100
ASTM's Revenue Growth (%) is ranked lower than
63% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ASTM: -100 )
ASTM' s 10-Year Revenue Growth (%) Range
Min: -100   Max: -9.6
Current: -100
-100
-9.6
EBITDA Growth (%) -2.1
ASTM's EBITDA Growth (%) is ranked higher than
53% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ASTM: -2.1 )
ASTM' s 10-Year EBITDA Growth (%) Range
Min: -30.3   Max: 5.3
Current: -2.1
-30.3
5.3
EPS Growth (%) -2.1
ASTM's EPS Growth (%) is ranked higher than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ASTM: -2.1 )
ASTM' s 10-Year EPS Growth (%) Range
Min: -29.1   Max: 5.3
Current: -2.1
-29.1
5.3
» ASTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ASTM



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/S 867.30
ASTM's P/S is ranked lower than
62% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. ASTM: 867.30 )
ASTM' s 10-Year P/S Range
Min: 13.33   Max: 802
Current: 867.3
13.33
802
EV-to-EBIT 0.2
ASTM's EV-to-EBIT is ranked higher than
95% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. ASTM: 0.2 )
ASTM' s 10-Year EV-to-EBIT Range
Min: 3.2   Max: 21.6
Current: 0.2
3.2
21.6

Valuation & Return

vs
industry		 vs
history
Earnings Yield (Greenblatt) 596.60
ASTM's Earnings Yield (Greenblatt) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ASTM: 596.60 )
ASTM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.6   Max: 620.9
Current: 596.6
4.6
620.9
Forward Rate of Return (Yacktman) -175.81
ASTM's Forward Rate of Return (Yacktman) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ASTM: -175.81 )
ASTM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.9   Max: 12.7
Current: -175.81
8.9
12.7

Business Description

Aastrom Biosciences, Inc. was incorporated in 1989 and are a regenerative medicine company focused on the development of innovative cell therapies to repair or regenerate damaged or diseased tissues. It is a regenerative medicine company focused on the clinical development of autologous cell products (cells collected from a patient and returned to that same patient) for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell (TRC) technology. Preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations, and are being investigated for their ability to aid in the regeneration of tissues such as cardiac, vascular, bone and neural. TRC-based products have been used in over 290 patients and are currently in various stages of development. Aastrom has developed a manufacturing system to produce human cells for clinical use, and all TRC-based products are produced using the firm's cell manufacturing system in centralized manufacturing facilities. The company is currently focused on utilizing its technology to produce expanded, patient specific multicellular products for use in severe, chronic ischemic cardiovascular indications. It owns 8 of these patents and 6 of these patents have been licensed exclusively from the University of Michigan; 5 of the University of Michigan patents will expire in 2012. Its products are subject to regulation as biological products under the Public Health Service Act and the Food, Drug and Cosmetic Act.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ATQN.Germany
» More Articles for ASTM

Headlines

Articles On GuruFocus.com
comment on ASTM Jan 10 2013 
Weekly CFO Sells Highlight: P, MTOR, PSSI, ASTM Jan 09 2012 
Weekly CFO Buys Highlight: OCWEN FINANCIAL Corp., Aastrom Biosciences Inc. Mar 13 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Aastrom Biosciences Inc. Reports Operating Results (10-Q/A) Feb 24 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 05 2010 
Aastrom Biosciences Inc. (ASTM) CEO Timothy M Mayleben buys 17,200 Shares Aug 31 2010 
Aastrom Biosciences Inc. (ASTM) CFO Scott Durbin buys 16,463 Shares Aug 27 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK